To include your compound in the COVID-19 Resource Center, submit it here.

Aerosolized Alpha-1 antitrypsin: Phase II started

Kamada began a double-blind, placebo-controlled, U.S. Phase II trial to evaluate 80 or 160 mg inhaled AAT twice daily

Read the full 194 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE